Skip to main content
Logo Logo Logo
  • Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Investors

    Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals

    Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients

    Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers

    Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links

    Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us

    Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up

Our News

Share this:

Expressing the Puzzling Challenges of hATTR Amyloidosis Through Art

January 9, 2020

Alnylam Pharmaceuticals

Over the summer, we asked the hereditary ATTR (hATTR) amyloidosis community to create and submit artistic representations expressing what it is like to live with the condition as part of an initiative called “The Art of Living with hATTR Amyloidosis.” The goal of the project is to raise awareness of hATTR amyloidosis – a rare, rapidly progressive and life-threatening disease – to help give voice to the community and support those who may feel isolated. 

We recently spoke with Peggy and her life partner Dan, who is living with hATTR amyloidosis, about their submission, At the Coffee Shop. 

At the Coffee Shop, submitted by Peggy to the "Art of Living with hATTR Amyloidosis" initiative.

Alnylam: Peggy, can you tell us a little bit about your artwork? 

Peggy: This piece is done in chalk pastels – which I use almost exclusively – and was created on the back of a puzzle. A lot of my artwork is inspired by the photos I take with my phone. I titled my submission for “The Art of Living with hATTR Amyloidosis” At the Coffee Shop, because the coffee shop is one of Dan’s and my favorite places to visit. Our local coffee shop is filled with great people, food, entertainment, and of course, coffee. 

Alnylam: What made you choose to create your submission on a puzzle? 

Peggy: hATTR amyloidosis has many facets and presents puzzling challenges regarding diagnosis and treatment. I hope that when other people see my piece, they will understand that this disease is complicated, but no matter what, when you look at all the pieces that have fallen into place, you can see it’s still possible to live life to the fullest. 

Alnylam: How did you feel when Dan was diagnosed with hATTR amyloidosis? 

Peggy: Dan is my life partner. We were married to each other and divorced. Now, we have been together longer than we were married. When I learned of Dan’s diagnosis, I immediately thought of his father’s suffering and early death and the pain it created for the entire family. This disease is something no one asks for and it takes fortitude to care for people with it. 

Alnylam: Dan, can you tell us more about your experience with hATTR amyloidosis? 

Dan: I was diagnosed with hATTR amyloidosis in 1996, shortly after my father passed away. After he passed, an autopsy revealed that he had undiagnosed hATTR amyloidosis and as a result, he was suffering from malnourishment, peripheral neuropathy, and carpal tunnel syndrome. Since being diagnosed, my daily life has changed radically. I had to retire early. Peggy and I also moved into a one level condo for safety and to ease daily worries, such as home maintenance and snow removal. I used to be an outdoorsman, but now instead of long walks, I rely on a scooter to go anywhere further than one block. 

Peggy and Dan in 2014

Alnylam: What impact has hATTR amyloidosis had on your family? 

Dan: I have a large family of twelve siblings – ten of whom are still living – and six have tested positive for hATTR amyloidosis. My oldest sibling died at age 69 during heart surgery and third oldest died at 70 of a heart attack. We suspect both of them may have had the condition as well. The disease has been difficult on my immediate family. Throughout it all, Peggy has been my rock, my “angel of mercy.” She dotes on me, tolerates my occasional crabbiness and I am humbly dependent on her to help me cope every day. 

Alnylam: How did you feel when you saw Peggy’s artwork, and what do you hope others will get out of seeing it? 

Dan: Peggy does a lot of pastel chalk drawings and I am always impressed by her talents. For those who are living with hATTR amyloidosis, they should know that the future is difficult, but not without hope. Get your affairs in order, follow your doctor’s orders, plan for the worst, and hope for the best. 

Tags

Patient Focus, Articles, Patient Advocacy, hATTR amyloidosis

Related Content See All News ›
Patient Focus Looking Beyond the Clinic: Putting Patients at the Center of Holistic Care in Transthyr ...
Patient Focus Alnylam’s Commitment to Health Literacy for All
Patient Focus First Consensus Recommendations for Holistic Care of People Living With Hereditary ATTR ...

Share this:

Categories

  • Leadership
  • Perspectives
  • RNAi
  • Patient Focus
  • Responsibility
  • Careers & Culture

Content Types

  • Articles
  • Podcasts
  • Presentations
  • Videos
See All News ›
Related Content See All News ›
Patient Focus Looking Beyond the Clinic: Putting Patients at the Center of Holistic Care in Transthyr ...
Patient Focus Alnylam’s Commitment to Health Literacy for All
Patient Focus First Consensus Recommendations for Holistic Care of People Living With Hereditary ATTR ...
See All News ›

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

  • Our Company
  • Our Science
  • Our Products
  • Our News
  • Investors
  • Medical Professionals
  • Patients
  • Job Seekers
  • Clinical Trials
  • Corporate Responsibility
  • Diversity, Equity & Inclusion
  • Press Releases
  • Capella
  • Medical Resources (RNAi Science)
  • Contact Us
  • Sign Up For Updates
  • Privacy Policy
  • Media Kit
  • Legal Notice
  • Site Map
  • Sign Up For Updates

Copyright ©  Alnylam Pharmaceuticals, Inc. — All Rights Reserved

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site